ECSP15043422A - Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina - Google Patents

Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina

Info

Publication number
ECSP15043422A
ECSP15043422A ECIEPI201543422A ECPI201543422A ECSP15043422A EC SP15043422 A ECSP15043422 A EC SP15043422A EC IEPI201543422 A ECIEPI201543422 A EC IEPI201543422A EC PI201543422 A ECPI201543422 A EC PI201543422A EC SP15043422 A ECSP15043422 A EC SP15043422A
Authority
EC
Ecuador
Prior art keywords
protein
procedure
formation
increase
pyroglutamic acid
Prior art date
Application number
ECIEPI201543422A
Other languages
English (en)
Inventor
Stephen Waugh
Barbara Thorne
Schravendijk Marie Rose Van
Original Assignee
Mabxience S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabxience S A filed Critical Mabxience S A
Publication of ECSP15043422A publication Critical patent/ECSP15043422A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina. Un procedimiento para la conversion de un residuo de glutamina y/o acido glutamico N-terminal de una proteina en acido piroglutamico en un procedimiento de purificacion.
ECIEPI201543422A 2013-04-04 2015-10-14 Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina ECSP15043422A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162241 2013-04-04

Publications (1)

Publication Number Publication Date
ECSP15043422A true ECSP15043422A (es) 2017-03-31

Family

ID=48044678

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201543422A ECSP15043422A (es) 2013-04-04 2015-10-14 Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina

Country Status (18)

Country Link
US (1) US10400042B2 (es)
EP (1) EP2981553A1 (es)
JP (1) JP2016523812A (es)
KR (1) KR20150138273A (es)
CN (1) CN105121469A (es)
AR (1) AR095977A1 (es)
AU (1) AU2014247034B2 (es)
BR (1) BR112015025106A2 (es)
CA (1) CA2907766A1 (es)
EC (1) ECSP15043422A (es)
HK (1) HK1221472A1 (es)
MX (1) MX2015014038A (es)
RU (1) RU2015147187A (es)
SA (1) SA515361251B1 (es)
SG (2) SG10201708088WA (es)
TW (1) TW201444863A (es)
UY (1) UY35517A (es)
WO (1) WO2014161940A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985542C (en) 2015-05-20 2023-10-10 Amgen Inc. Triazole agonists of the apj receptor
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3676280B1 (en) * 2017-08-30 2025-03-19 Fresenius Kabi Deutschland GmbH Method for purifying anti-il-6 receptor antibodies
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation
CN112110983A (zh) * 2019-06-21 2020-12-22 正大天晴药业集团股份有限公司 蛋白质的纯化方法
CN112725398B (zh) * 2019-10-29 2022-07-01 中国食品发酵工业研究院有限公司 一种具有辅助降血糖功能的豌豆肽及其制备方法
US11598116B1 (en) 2020-10-01 2023-03-07 Florida Aluminum Systems, Llc Mounting system for separating and connecting fencing slabs
HUP2400216A1 (hu) * 2024-04-17 2025-10-28 Richter Gedeon Nyrt N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20060286629A1 (en) * 2003-12-19 2006-12-21 Norby Inga S N Processing of Peptides and Proteins
DE602004032379D1 (de) 2003-12-19 2011-06-01 Novo Nordisk As Prozessierung von peptiden und proteinen
AU2005263334C1 (en) 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EP1685161A1 (en) 2004-08-30 2006-08-02 Lonza Biologics plc Affinity- plus ion exchange-chromatography for purifying antibodies
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
BRPI0817182A2 (pt) * 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
US8815242B2 (en) 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
CN102492040B (zh) * 2011-12-29 2014-06-25 嘉和生物药业有限公司 一种抗her2或/和抗her3抗体蛋白的纯化方法

Also Published As

Publication number Publication date
JP2016523812A (ja) 2016-08-12
AU2014247034B2 (en) 2018-08-23
CA2907766A1 (en) 2014-10-09
SG10201708088WA (en) 2017-10-30
UY35517A (es) 2014-10-31
RU2015147187A (ru) 2017-05-23
KR20150138273A (ko) 2015-12-09
WO2014161940A1 (en) 2014-10-09
SG11201507815XA (en) 2015-10-29
CN105121469A (zh) 2015-12-02
HK1221472A1 (zh) 2017-06-02
AR095977A1 (es) 2015-11-25
US10400042B2 (en) 2019-09-03
BR112015025106A2 (pt) 2017-10-10
MX2015014038A (es) 2016-06-02
EP2981553A1 (en) 2016-02-10
RU2015147187A3 (es) 2018-02-28
AU2014247034A1 (en) 2015-10-01
US20160060349A1 (en) 2016-03-03
TW201444863A (zh) 2014-12-01
SA515361251B1 (ar) 2018-07-01

Similar Documents

Publication Publication Date Title
ECSP15043422A (es) Un procedimiento para aumentar la formacion de acido piroglutamico de una proteina
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
IN2014DE00193A (es)
UA116920C2 (uk) Інгібітори fgfr4
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
MX375524B (es) Anticuerpos anti-axl.
UY34675A (es) ?proceso y aparato para tratar superficies de metal?.
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
SG10201811017QA (en) Novel antibody frameworks
EA201600429A1 (ru) Способ очистки 2,5-дихлорфенола
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
IN2013MU00848A (es)
IN2013MU03641A (es)
EA201690263A1 (ru) Улучшенные способы получения перампанеля
IN2013MU01113A (es)
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
CL2017001383A1 (es) Proceso para la fabricación de anhídrido carboxílico
MX384260B (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
IN2013MU03768A (es)